The direct answer: Gala starts at $79/mo for semaglutide and $129/mo for tirzepatide on the annual plan, at its current Pre-Black Friday prices. Here’s the full breakdown, verified against our review of all 22 certified programs.
Across the 22 LegitScript-certified programs we review, starting prices run from $49 to $249 per month. Gala starts at $79, at the median and below most of our top-rated programs. The cheapest option isn’t automatically the right one: in 2026 retention data, cost is the top reason people quit GLP-1 treatment, and the programs people actually stay with are the ones whose ongoing price fits their budget. See our full price comparison.
Our Gala rating already accounts for pricing transparency; anything that changes gets reflected in the full review.
Gala starts at $79/mo for semaglutide and $129/mo for tirzepatide on the annual plan, at its current Pre-Black Friday prices. Final pricing is confirmed at checkout after a licensed clinician reviews your intake.
Our review checks every program for teaser pricing, separate consultation fees, dose-escalation increases, and shipping or cancellation costs. Details for Gala are below; always confirm the ongoing monthly price at checkout.
Gala is rated 9.7/10, our #2 pick, and starts below most of the 22 certified programs we review ($49-$249/mo range). Whether it fits depends on your budget and support needs; our quiz compares all options.
No insurance needed.
How Gala stacks up against the highest-rated programs in our 2026 rankings.
Pricing verified November 2026 and subject to change; the price at each program’s checkout is final. This page is educational, not medical advice. GLP-1 medications require a prescription and are used alongside a reduced-calorie diet and exercise.
Price changes, new program reviews, and plain-English GLP-1 updates, straight to your inbox. Independent, and never sponsored by the programs we review.
By joining, you agree to receive emails from GLP One Guide. Unsubscribe anytime. We never sell your email. See our Privacy Policy.